Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Knockout EBV-CTLs for Advanced EBV Malignancies
NCT03044743Phase 2Unknown
- Start
- Apr 2017
- Primary completion
- Mar 2020
- Modality
- CRISPR-Cas9, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of programmed cell death 1 knockout epstein-barr virus-specific cytotoxic t lymphocytes in Gastric carcinoma (GC), nasopharyngeal carcinoma (NPC), T-cell lymphoma, Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL). Status: unknown.
02
Drugs
programmed cell death 1 knockout epstein-barr virus-specific cytotoxic t lymphocytes
03
Conditions
Gastric carcinoma (GC)nasopharyngeal carcinoma (NPC)T-cell lymphomaHodgkin lymphoma (HL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03044743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03044743.